Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells
Human Pathology, Volume 41, No. 6, Year 2010
Notification
URL copied to clipboard!
Description
Overexpression of histone deacetylases has been reported in various human malignancies; however, the expression of histone deacetylases in endometrial tissue is not fully understood. In the present study, the expression of histone deacetylase 1, histone deacetylase 2, and Ki-67 was examined immunohistochemically in 30 normal and 66 malignant endometrial tissue samples. The results were expressed as a positivity index and compared with the positivity index for Ki-67 and rates of patient survival. The effect of 2 histone deacetylase inhibitors, trichostatin A and apicidine, on cell proliferation and the expression of cell cycle regulators such as cyclins (D1, E, and A), p21, p27, and p16 were investigated using 6 endometrial carcinoma cell lines. The positivity index for histone deacetylase 1 (79.8 ± 33.0, mean ± SD) and histone deacetylase 2 (106.3 ± 41.9) was higher in endometrial carcinoma than the normal endometrium, with a significant difference for histone deacetylase 2. The positivity index for histone deacetylase 2 was significantly increased in higher-grade carcinomas (positivity index for grade 3, 124.9 ± 28.4) compared with grade 1 tumors (86.0 ± 41.0) and was positively correlated with that for Ki-67. In addition, patients with histone deacetylase 2-positive carcinomas had a poor prognosis compared with those with histone deacetylase 2-negative carcinoma (P = .048). Treatment with trichostatin A or apicidine suppressed the proliferation in all cell lines examined, in association with increased expression of p21 and down-regulation of cyclin D1 and cyclin A expression. These results indicated that increased histone deacetylase 2 expression is involved in the acquisition of aggressive behavior by endometrial carcinoma and suggest histone deacetylase inhibitor to be a promising anticancer drug for this carcinoma. © 2010 Elsevier Inc. All rights reserved.
Authors & Co-Authors
Fakhry, Hussein
Egypt, Asyut
Assiut University
Miyamoto, Tsutomu
Japan, Matsumoto
Shinshu University Faculty of Medicine
Kashima, Hiroyasu
Japan, Matsumoto
Shinshu University Faculty of Medicine
Suzuki, Akihisa
Japan, Matsumoto
Shinshu University Faculty of Medicine
Ke, He
China, Guangzhou
Sun Yat-sen University
Konishi, Ikuo
Japan, Kyoto
Kyoto University Faculty of Medicine
Shiozawa, Tanri
Japan, Matsumoto
Shinshu University Faculty of Medicine
Statistics
Citations: 7
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1016/j.humpath.2009.11.012
ISSN:
00468177
Research Areas
Cancer
Health System And Policy